Timothy P. Walbert Joins Latigo Biotherapeutics Leadership
In an exciting development for the biopharmaceutical community, Latigo Biotherapeutics has announced the appointment of Timothy P. Walbert as the new chair of its board of directors. With an impressive track record spanning over 30 years in the biopharmaceutical industry, Mr. Walbert's expertise is poised to drive Latigo forward as it develops innovative non-opioid pain management solutions.
Experience and Vision
Mr. Walbert is not new to the challenges and opportunities in the biotech realm. His previous role as chairman and CEO at Horizon Therapeutics set a benchmark for leadership within the industry. Under his guidance, Horizon experienced significant growth and innovation, culminating in its acquisition by Amgen for a substantial $28.3 billion. This acquisition illustrates his capability to lead organizations through transformative phases, a skill that will undoubtedly benefit Latigo.
Commitment to Non-Opioid Pain Management
Latigo Biotherapeutics is committed to developing best-in-class pain relief solutions that minimize the risk of addiction. The company is currently focusing on a new class of Nav1.8 inhibitors, which may provide effective and non-opioid alternatives for managing pain. Mr. Walbert emphasized his eagerness to support Latigo's mission: "I am honored to join Latigo Biotherapeutics as board chair and support the company's vision of addressing significant unmet needs in chronic and acute pain management." His dedication aligns perfectly with the company's goal of offering patient-centered solutions.
A Strong Foundation for Future Growth
As Mr. Walbert steps into his new role, he replaces Nancy Stagliano, Ph.D. Dr. Stagliano, who served as chair for four years, remains on the board, ensuring continuity in leadership and counsel as the company advances its strategies. Latigo's CEO, Nima Farzan, expressed gratitude for Dr. Stagliano's contributions and welcomed Mr. Walbert, acknowledging his vast industry experience as an invaluable asset.
Previous Accomplishments
Before leading Horizon, Mr. Walbert held pivotal positions at several companies, including serving as president and CEO of IDM Pharma Inc., which eventually caught the attention of Takeda America Holdings, resulting in its acquisition. His experience extends to senior roles at NeoPharm Inc. and Abbott (now AbbVie), where he played a crucial part in launching HUMIRA®, a groundbreaking treatment for various conditions. His extensive career reflects a deep commitment to innovation and the commercialization of critical pain therapies.
Current Involvement beyond Latigo
Aside from his role at Latigo, Mr. Walbert contributes his insights to various organizations and boards in the biotech community. He is involved with Mirum Pharmaceuticals, Century Therapeutics, and several others aimed at fostering innovation in life sciences. His participation in advisory councils and industry groups highlights his commitment to advancing public health through strategic initiatives.
About Latigo Biotherapeutics
Latigo Biotherapeutics is a private clinical-stage biotechnology firm focused on developing cutting-edge non-opioid pain relief solutions. The company thrives on innovation, seeking to provide effective, rapid-acting therapies that mitigate the risk of addiction associated with traditional pain medications. Supported by prominent investors, Latigo is well-positioned to make significant contributions to pain management strategies.
Frequently Asked Questions
What role does Timothy P. Walbert have in Latigo Biotherapeutics?
Timothy P. Walbert has been appointed as the chair of Latigo Biotherapeutics' board of directors.
What are Latigo Biotherapeutics' main focuses?
Latigo Biotherapeutics is dedicated to developing innovative non-opioid pain medicines targeting the underlying sources of pain.
How does Mr. Walbert's experience benefit Latigo?
Mr. Walbert brings extensive biopharmaceutical industry experience, having previously led Horizon Therapeutics through significant growth and innovation.
What was Mr. Walbert's previous position before joining Latigo?
Before joining Latigo, Mr. Walbert served as chairman and CEO of Horizon Therapeutics.
What is the vision of Latigo Biotherapeutics?
Latigo Biotherapeutics aims to provide effective and safer alternatives for people suffering from acute and chronic pain, enhancing patient outcomes without the risks associated with opioid medications.
